A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection

Journal of Virology

Volumn 85, Issue 24, 2011, Pages 13253-13259

  Longet, Stéphanie ^a   Schiller, John T ^b   Bobst, Martine ^a   Jichlinski, Patrice ^a   Nardelli Haefliger, Denise ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; GOLD STANDARD; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REPRODUCTIVE TRACT INFECTIONS;

ANIMALIA; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; MURINAE; MUS; PAPILLOMAVIRIDAE;

EID: 84855823916     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06093-11     Document Type: Article

References (33)

1. Alphs, H. H., et al. 2008. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly crossneutralizing epitope of L2. Proc. Natl. Acad. Sci. USA 105:5850-5855.
2. Balmelli, C., et al. 1998. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J. Virol. 72:8220-8229.
3. Breitburd, F., et al. 1995. Immunization with viruslike particles from cottontail rabbit papillomavirus /CRPV) can protect against experimental CRPV infection. J. Virol. 69:3959-3963.
4. Brown, D. R., et al. 2011. The humoral response to Gardasil over four years as defined by total IgG and competitive luminex immunoassay. Human Vaccines 7:230-238.
5. Buck, C., D. V. Pastrana, D. R. Lowy, and J. T. Schiller. 2004. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78:751-757.
6. Christensen, N. D., et al. 1996. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223:174-184.
7. Cuburu, N., et al. 2009. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J. Immunol. 183:7851-7859.
8. Day, P. M., R. Gambhira, R. B. Roden, D. R. Lowy, and J. T. Schiller. 2008. Mechanisms of human papillomavirus type 16 neutralization by l2 crossneutralizing and l1 type-specific antibodies. J. Virol. 82:4638-4646.
9. Day, P. M., et al. 2010. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 8:260-270.
10. Day, P. M., et al. 2007. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J. Virol. 81: 8784-8792.
11. Dessy, F. J., et al. 2008. Correlation between direct ELISA, single epitopebased inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Human Vaccines 4:425-434.
12. Einstein, M. H., et al. 2009. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Human Vaccines 5:705-719.
13. Fraillery, D., et al. 2007. Ty21a expressing human papillomavirus type 16 L1 as a potential live Salmonella vaccine against cervical cancer and typhoid fever. Clin. Vaccine Immunol. 14:1285-1295.
14. Fraillery, D., N. Zosso, and D. Nardelli-Haefliger. 2009. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles. Vaccine 27:2326-2334.
15. Harper, D. M., et al. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-1765.
16. Hildesheim, A., et al. 1999. Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures. J. Immunol. Methods 225:131-143.
17. Hopkins, S., et al. 1995. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect. Immun. 63:3279-3286.
18. Jagu, S., et al. 2009. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J. Natl. Cancer Inst. 101: 782-792.
19. Joura, E. A., et al. 2008. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26: 6844-6851.
20. Karanam, B., et al. 2009. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine 27:1040-1049.
21. Kemp, T. J., et al. 2008. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 26:3608-3616.
22. Nardelli-Haefliger, D., et al. 1997. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect. Immun. 65:3328-3336.
23. Nardelli-Haefliger, D., et al. 2003. Specific antibody levels at the cervix during the menstrual-cycle of women vaccinated with human papillomavirus 16 virus-like particles. J. Natl. Cancer Inst. 95:1128-1137.
24. Omland, K. S., A. Brys, D. Lansky, K. Clement, and F. Lynn. 2008. Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species. Clin. Vaccine Immunol. 15:946-953.
25. Opalka, D., et al. 2003. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin. Diagn. Lab. Immunol. 10:108-115.
26. Paavonen, J., et al. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-314.
27. Parkin, D. M. 2006. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118:3030-3044.
28. Pastrana, D. V., et al. 2004. Reactivity of human sera in a sensitive, highthroughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205-216.
29. Revaz, V., et al. 2007. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antiviral Res. 76:75-85.
30. Roberts, J. N., et al. 2007. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 13:857-861.
31. Suzich, J. A., et al. 1995. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. U. S. A. 92:11553-11557.
32. Villa, L. L., et al. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11,16 and 18) L1-virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6:271-278.
33. Villa, L. L., et al. 2006. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95:1459-1466.